Audited Supplier
In This Store
Chempro is a leading manufacturer and supplier of pharmaceuticals and developer of technologies for Key Starting Intermediates, APIs, Pellets, Finished Dosage Forms, OTC & Nutraceuticals, Impurities and Reference Standards. We are a globally renowned supply chain and sourcing partner to 50+ leading pharmaceutical companies across Asia, Europe, North, Central and South America, having 40+ years of experience. It is present in 40+ countries and offers a one-stop solution to Pharmaceutical customers worldwide. We are an ISO-compliant company having access to facilities with WHO-GMP, KFDA, PMDA, EU-GMP, and USFDA and committed to ensuring the profitable growth of its worldwide pharmaceutical partners.
Year of Establishment: 2006
Total Assets(USD):
Total Number of Staff:
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Other Competitive Advantages: We offer a comprehensive range of biosimilar products designed to enhance access to vital treatments across various therapeutic areas. Our products adhere to the highest regulatory standards, ensuring both patient safety and therapeutic equivalence, and are available in ready-to-use form
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094
![N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAc) - Salcaprozate sodium](https://eimg.pharmasources.com/image/20250407/glWQx8r7zi06C4pGLlnVnwh4wzxTuy5ctYzly6p1.png!200)
![5′-Bromo-1′-phenyl[2,3′-bipyridin]-6′(1′H)-one](https://eimg.pharmasources.com/image/20250407/eMVZAB40H1vejbYQ830D1KkrwtU5lBJvLThWMZce.png!200)
![2-(5-Bromo-2-fluorobenzyl)benzo[b]thiophene](https://eimg.pharmasources.com/image/20250407/PgkxbQ8zenDSBIIan2Gutl1vjmmgo7dFYJmuUU4a.png!200)
![Ethyl 4′-[2-(acetyloxy)ethoxy]-3′-bromo[1,1′-biphenyl]-4-carboxylate](https://eimg.pharmasources.com/image/20250407/dEX0NBylOBDzgR18KU8sQu75sSSpbHw3WUIkP9wb.png!200)
![1,1'-Biphenyl]-4-carboxylic acid, 3'-bromo-4'-hydroxy-, ethyl ester](https://eimg.pharmasources.com/image/20250407/FGiEpA22EHcRAxMfsnSvkQK6Kq09nfYVhGd5vxTq.png!200)
![4-[2-(4-Bromophenoxy)ethyl]morpholine](https://eimg.pharmasources.com/image/20250407/fPL9di44EonGxgSbe5VXCuyDAmnYKMWYWlRr7OnL.png!200)
![4-Thiazolidinone, 5-[(3-chloro-4-hydroxyphenyl)methylene]-3-(2-methylphenyl)-2-(propylimino)-, (2Z,5](https://eimg.pharmasources.com/image/20250407/4dNpYVWmO3OlSYvlxgsUmsrlaqzv6U1WRpu16uUr.png!200)
Pharma Sources Insight July 2025
